Lupin unveils Bromfenac Ophthalmic Solution, 0.075% in US
Mumbai: Global pharma major Lupin Limited has announced
the launch of Bromfenac Ophthalmic Solution, 0.075%, after having received an approval from the
United States Food and Drug Administration (U.S. FDA).
Bromfenac Ophthalmic Solution, 0.075% is a generic equivalent of BromSite Ophthalmic Solution,
0.075%, of Sun Pharmaceutical Industries Limited.
0.075%, of Sun Pharmaceutical Industries Limited.
It is indicated for the treatment of postoperative
inflammation and prevention of ocular pain in patients undergoing cataract surgery.
inflammation and prevention of ocular pain in patients undergoing cataract surgery.
Bromfenac Ophthalmic Solution 0.075% (RLD BromSite) had estimated annual sales of USD 15 million
in the U.S. (IQVIA MAT December 2023).
in the U.S. (IQVIA MAT December 2023).
Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The
Company develops and commercializes a wide range of branded and generic formulations, biotechnology
products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin
America (LATAM), Europe, and Middle East regions.
The Company specializes in the cardiovascular, anti-diabetic, and respiratory segments and has
a significant presence in the anti-infective, gastro-intestinal (GI), central nervous system (CNS), and women’s
health areas. The company
invested 7.9% of its revenue in research and development in FY23.
Lupin has 15 manufacturing sites, 7 research centers.
Company develops and commercializes a wide range of branded and generic formulations, biotechnology
products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin
America (LATAM), Europe, and Middle East regions.
The Company specializes in the cardiovascular, anti-diabetic, and respiratory segments and has
a significant presence in the anti-infective, gastro-intestinal (GI), central nervous system (CNS), and women’s
health areas. The company
invested 7.9% of its revenue in research and development in FY23.
Lupin has 15 manufacturing sites, 7 research centers.
Facebook Comments
